(Q42950831)

11 November 2017

title

In vitro activity of isavuconazole against 140 reference fungal strains and 165 clinically isolated yeasts from Japan (English)

1 reference

11 November 2017

Toshikazu Yamazaki

1

1 reference

11 November 2017

Yukiko Inagaki

2

1 reference

11 November 2017

Toshihiko Fujii

3

1 reference

11 November 2017

Jun Ohwada

4

1 reference

11 November 2017

Masao Tsukazaki

5

1 reference

11 November 2017

Isao Umeda

6

1 reference

11 November 2017

Kazuko Kobayashi

7

1 reference

11 November 2017

Nobuo Shimma

8

1 reference

11 November 2017

Mikio Arisawa

10

1 reference

11 November 2017

Malcolm G. P. Page

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20674282

14 June 2024

language of work or name

1 reference

31 July 2010

1 reference

full work available at URL

11 November 2017

https://api.elsevier.com/content/article/PII:S092485791000244X?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.003

https://api.elsevier.com/content/article/PII:S092485791000244X?httpAccept=text/plain

14 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.003

International Journal of Antimicrobial Agents

14 June 2024

published in

1 reference

11 November 2017

volume

36

1 reference

11 November 2017

issue

4

1 reference

11 November 2017

page(s)

324-331

1 reference

Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997.

11 November 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.003

Epidemiology of visceral mycoses: analysis of data in annual of the pathological autopsy cases in Japan

14 June 2024

2

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.003

Increase in aspergillosis and severe mycotic infection in patients with leukemia and MDS: comparison of the data from the Annual of the Pathological Autopsy Cases in Japan in 1989, 1993 and 1997.

14 June 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.003

Review of 49 neonates with acquired fungal sepsis: further characterization

14 June 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.003

Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients

14 June 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.003

Outbreak of Candida rugosa candidemia: an emerging pathogen that may be refractory to amphotericin B therapy

14 June 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.003

Change in colony morphology of Candida lusitaniae in association with development of amphotericin B resistance

14 June 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.003

Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient

14 June 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.003

Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial

14 June 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.003

Drug-drug interaction between itraconazole and the antiretroviral drug lopinavir/ritonavir in an HIV-1-infected patient with disseminated histoplasmosis

14 June 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.003

Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy

14 June 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.003

Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis

14 June 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.003

Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance

14 June 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.003

Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin.

14 June 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.003

Design, synthesis and antifungal activity of a novel water soluble prodrug of antifungal triazole

14 June 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.003

In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species

14 June 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.003

New generation azole antifungals in clinical investigation

14 June 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.003

In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species

14 June 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.003

In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba

14 June 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.003

Broth dilution testing of Candida albicans susceptibility to ketoconazole

14 June 2024

24

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.003

Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods

14 June 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.003

Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus.

14 June 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.003

Azole-resistance in Aspergillus: proposed nomenclature and breakpoints

14 June 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.003

In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing

14 June 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.003

In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates.

14 June 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.003

In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp.

14 June 2024

31

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.003

Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus

14 June 2024

32

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.003

In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes

14 June 2024

34

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.003

Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants

14 June 2024

35

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.003

Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in h

14 June 2024

37

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.003

Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers

14 June 2024

38

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.003

In vitro activities of eight antifungal drugs against 70 clinical and environmental isolates of Alternaria species

14 June 2024

39

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.003

Antimicrobial prophylaxis in febrile neutropenia

14 June 2024

40

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.003

Management of Candida species infections in critically ill patients

14 June 2024

41

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.003

14 June 2024

Identifiers

1 reference

11 November 2017

1 reference